Zhejiang Wenda Pharma reports Phase II BET inhibitor trial data

Zhejiang Wenda Pharma is set to present phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, at the 2026 ESMO Annual Meeting. The study, conducted in Chinese patients with advanced NUT carcinoma (NC), revealed a 30% objective response rate (ORR) and a 47.5% disease control rate (DCR). The trial also showed median progression-free survival (PFS) and overall survival (OS) of 2.76 and 9.33 months, respectively.

NHWD-870 HCl, a novel oral BET inhibitor, has been granted breakthrough therapy designation by the China National Medical Products Administration (NMPA) for advanced thoracic NUT carcinoma.

Brief written by urgent.news from Vietnam Investment Review's own syndicated text. Machine-written — may contain errors; check the original before relying on it.